Format

Send to

Choose Destination
  • Filters activated: Field: Title Word. Clear all
Alzheimers Dement (N Y). 2018 Apr 26;4:165-172. doi: 10.1016/j.trci.2018.03.006. eCollection 2018.

Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites.

Author information

1
Department of Neurology, Massachusetts General Hospital/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
2
Department of Mathematics and Statistics, University of Vermont, Burlington, VT, USA.
3
Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
4
Department of Psychiatry, Indiana University, Indianapolis, IA, USA.
5
Division of Cardiology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
6
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
7
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
8
Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.
9
Section of Cardiology, Department of Medicine, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA.

Abstract

Introduction:

The relationship between serum galectin-3 and incident cognitive impairment was analyzed in the Reasons for Geographic and Racial Differences in Stroke study.

Methods:

Baseline galectin-3 was measured in 455 cases of incident cognitive impairment and 546 controls. Galectin-3 was divided into quartiles based on the weighted distribution in the control group, and the first quartile was the referent.

Results:

There was an increasing odds of cognitive impairment across quartiles of galectin-3 (odds ratios, 1.00 [0.68-1.46], 1.45 [1.01-2.10], and 1.58 [1.10-2.27] relative to the quartile 1; P trend = .003) in an unadjusted model, which persisted after adjusting for age, sex, and race (P = .004). Adjustment for cardiovascular risk factors greatly attenuated this association (odds ratios, 0.97 [0.60-1.57], 1.52 [0.94-2.46], and 1.27 [0.76-2.12]; P = .15). The association differed by diabetes status (P interaction, .007). Among nondiabetics (293 cases, 411 controls), those with galectin-3 in the fourth compared with first quartile had an odds ratio of 1.6 (0.95-2.99; P trend, .02). In diabetics, the odds ratio was 0.23 (0.04-1.33).

Discussion:

Serum galectin-3 was associated with increased risk of incident cognitive impairment in a large cohort study of blacks and whites but only in nondiabetics.

KEYWORDS:

Biomarkers; Cognitive impairment; Epidemiology; Galectin-3; Incidence; Risk factors

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center